NEW HAVEN, Conn. (WTNH) — The Board of Directors at New Haven based Alexion Pharmaceuticals, Inc., announced today that David Brennan will serve as Interim Chief Executive Officer.
The move is effective immediately. Brennan is former CEO and Executive Director of AstraZeneca PLC, and has been a member of the Alexion Board of Directors since July 2014.
Brennan replaces David Hallal who has resigned for personal reasons. Mr. Hallal will also vacate his seat on the Board of Directors.
Alexion’s Board also announced that David J. Anderson will join the company as Chief Financial Officer. Anderson is a former Senior Vice President and CFO at Honeywell. He replaces Vikas Sinha, who left Alexion to pursue other opportunities.
In discussing the changes, Leonard Bell, M.D., Chairman of the Board of Directors, said, “This leadership transition comes during a period of great strength and momentum. The fundamentals of Alexion are very strong. We have three highly effective therapies and a robust rare disease pipeline. We are well-positioned for sustainable growth. Moreover, we have a clear strategy to continue our mission to develop and deliver transformative therapies for patients with devastating and rare diseases.”